SECURITY LEVEL 5 // RESTRICTED ACCESS // BIOLOGICAL HAZARD
DIVISION 04 // CLASSIFIED // NO ADMITTANCE

BIO-RESEARCH & GENETICS

Unlocking the genetic potential of the universe.

The Frontier of Life

Our Bio-Research division is the most secretive and profitable arm of Weyland Corp. We specialize in the study of indigenous exoplanetary biological specimens, deriving life-saving pharmaceuticals and genetic enhancements that have extended the average human lifespan by over forty years.

However, the true goal of the division is much deeper. We seek the key to cellular regeneration and the mastery of the evolutionary process itself. Through synthetic-biological synthesis, we are creating a new future for mankind.

[ REDACTED VISUAL: SPECIMEN 001 ]

INTERNAL RESEARCH LOGS

02.14.2122
Project "Sisyphus" // Status: OPERATIONAL

Initial testing on the Reticu-Strain-A has yielded a 400% increase in localized tissue regeneration. Specimen stability remains a primary concern for field deployment.

01.05.2122
Classification Update: LV-223 Samples

Biochemical analysis of the black-fluid deposits reveals a highly reactive mutagen. Engineering team is currently working on an emotion-dampening delivery system for synthetic integration.

12.12.2121
Pharmaceutical Milestone: Rejuvenation-X

Phase 3 trials on terrestrial test subjects completed. Mortality rate reduced to < 0.1%. Market rollout scheduled for Tier 1 Shareholders by Q2.

Bio-Containment Protocols

All Weyland Corp research facilities operate under strict Class-5 containment protocols. In the event of a primary breach, automated thermal-scuttling procedures will initiate within 30 seconds to ensure the safety of the surrounding region and the integrity of corporate secrets.